Physician profile
Michael Gorin
NPI 1881991495
$200,166.63
in general payments reported to CMS, 2019-2025
20 companies · $7,353 in 2025
The $7,353 reported for 2025 was more than what 92% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $48K · 2021: $71K · 2022: $58K · 2023: $8,270 · 2024: $7,348 · 2025: $7,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $1,650 · Honoraria: $1,289 · Food and Beverage: $1,193 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,803.68 |
| Travel and Lodging | $1,650.33 |
| Honoraria | $1,289.00 |
| Food and Beverage | $1,192.55 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corbin Clinical Resources | $81,781.93 | 2020-2022 | |
| Koelis INC. | $53,160.01 | 2020-2025 | |
| Progenics Pharmaceuticals, INC. | $27,347.87 | 2020-2025 | Pylarify |
| Blue Earth Diagnostics | $14,272.92 | 2020-2022 | |
| Ambu A/S | $7,987.68 | 2023-2024 | |
| Ambu INC. | $4,597.96 | 2021-2025 | |
| Telix Pharmaceuticals | $3,948.93 | 2022-2025 | Illuccix |
| Bk Medical Holding Company INC. | $3,862.50 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $1,907.50 | 2022 | |
| Cook Incorporated | $400.00 | 2025 | |
| Astellas Pharma US INC | $284.92 | 2020-2021 | |
| Healthtronics Stone Solutions, LLC | $210.66 | 2019 | |
| Allergan, INC. | $86.54 | 2021-2022 | |
| Pfizer INC. | $75.12 | 2022 | |
| Boston Scientific Corporation | $65.10 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $59.47 | 2022 | |
| Janssen Biotech, INC. | $51.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Axonics, INC. | $18.14 | 2021 | |
| Acerus Pharmaceuticals Corporation | $12.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gorin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.